D Yoshiga Y Yamashita I Nakamichi T Tanaka K Yamauchi N Yamamoto S Nogami T Kaneuji S Mitsugi T Sakurai H Kiyomiya K Tominaga Y Morimoto T Takahashi
10.1007/s00198-013-2277-x
Osteoporos Int
2013 Aug;24(8):2365-9.
CC BY-NC
https://pubmed.ncbi.nlm.nih.gov/23371327/
Bisphosphonate-Associated Osteonecrosis of the Jaw / drug therapy Bone Density Conservation Agents / administration & dosage Teriparatide / administration & dosage
Bisphosphonate-Associated Osteonecrosis of the Jaw / drug therapy Bone Density Conservation Agents / administration & dosage Teriparatide / administration & dosage Case Reports Comparative Study Aged, 80 and over Biomarkers / blood Bisphosphonate-Associated Osteonecrosis of the Jaw / blood Bisphosphonate-Associated Osteonecrosis of the Jaw / diagnostic imaging Bone Density Conservation Agents / therapeutic use Collagen Type I / blood Drug Administration Schedule Female Humans Injections, Intravenous Peptide Fragments / blood Peptides / blood Procollagen / blood Radiography Teriparatide / therapeutic use Treatment Outcome Biomarkers Bone Density Conservation Agents Collagen Type I Peptide Fragments Peptides Procollagen collagen type I trimeric cross-linked peptide procollagen Type I N-terminal peptide Teriparatide
PMC3706737
23371327
Weekly teriparatide injections successfully treated advanced bisphosphonate-related osteonecrosis of the jaws
2013